EcoR1 Capital LLC acquired a new position in WAVE Life Sciences Ltd. (NASDAQ:WVE) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,000 shares of the company’s stock, valued at approximately $275,000.
Other hedge funds have also modified their holdings of the company. Schwab Charles Investment Management Inc. increased its position in WAVE Life Sciences by 6.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 30,707 shares of the company’s stock valued at $845,000 after buying an additional 1,881 shares in the last quarter. Geode Capital Management LLC increased its position in WAVE Life Sciences by 4.6% in the first quarter. Geode Capital Management LLC now owns 76,478 shares of the company’s stock valued at $2,103,000 after buying an additional 3,397 shares in the last quarter. Vanguard Group Inc. increased its position in WAVE Life Sciences by 5.2% in the first quarter. Vanguard Group Inc. now owns 153,781 shares of the company’s stock valued at $4,229,000 after buying an additional 7,550 shares in the last quarter. Marshall Wace North America L.P. purchased a new position in WAVE Life Sciences during the first quarter valued at $835,000. Finally, MARSHALL WACE ASIA Ltd purchased a new position in WAVE Life Sciences during the first quarter valued at $835,000. 56.84% of the stock is owned by hedge funds and other institutional investors.
WAVE Life Sciences Ltd. (NASDAQ:WVE) traded up 7.69% during midday trading on Friday, reaching $21.00. The company had a trading volume of 124,724 shares. WAVE Life Sciences Ltd. has a 12 month low of $17.41 and a 12 month high of $40.15. The firm’s 50-day moving average price is $20.83 and its 200 day moving average price is $26.28. The firm’s market capitalization is $582.06 million.
WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Wednesday, May 10th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by $0.12. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.80 million. WAVE Life Sciences had a negative return on equity of 48.16% and a negative net margin of 3,172.14%. Equities analysts anticipate that WAVE Life Sciences Ltd. will post ($3.25) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “EcoR1 Capital LLC Acquires Shares of 10,000 WAVE Life Sciences Ltd. (WVE)” was first published by sleekmoney and is owned by of sleekmoney. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://sleekmoney.com/ecor1-capital-llc-acquires-shares-of-10000-wave-life-sciences-ltd-wve/1916427.html.
Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of WAVE Life Sciences in a research report on Monday, March 27th. Jefferies Group LLC reissued a “buy” rating and set a $42.00 price objective on shares of WAVE Life Sciences in a research report on Wednesday, April 26th. JMP Securities reissued an “outperform” rating and set a $40.00 price objective on shares of WAVE Life Sciences in a research report on Friday, June 9th. Finally, ValuEngine downgraded WAVE Life Sciences from a “hold” rating to a “sell” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $42.00.
In related news, Director Masaharu Tanaka sold 433,825 shares of the firm’s stock in a transaction that occurred on Wednesday, March 29th. The stock was sold at an average price of $24.91, for a total value of $10,806,580.75. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 62.25% of the company’s stock.
WAVE Life Sciences Company Profile
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for WAVE Life Sciences Ltd. (NASDAQ:WVE).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/ecor1-capital-llc-acquires-shares-of-10000-wave-life-sciences-ltd-wve/1916427.html
Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.